NRXS (Neuraxis) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRXS Neuraxis Inc NRXS
42 GF Score
Price $6.24
GF Value $2.94
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Neuraxis Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

NRXS
42GF Score
Neuraxis Inc NRXS
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuraxis (NRXS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued. The current stock price of $6.24 is trading 112.2% above its estimated GF Value™ of $2.94. GuruFocus considers Neuraxis to be Significantly Overvalued.

Key valuation signals for NRXS:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $2.94 vs. price of $6.24 (112.2% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuraxis Business Description

Address 11611 North Meridian Street, Suite 330, Carmel, IN, USA, 46032
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score

Get the complete analysis for NRXS

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price
$2.94
GF Value